天美传媒

A new test for detecting biomarkers for cancer and diabetes is more than 1000x more detailed and 100% faster than existing methods, new research by the 天美传媒 suggests.

Developed to undertake a detailed study of collagen, the researchers argue that the same methodology can be used with any protein-based sample and is currently being tested with cancer cells and proteins relevant to Type II diabetes.

Researchers at the 天美传媒 have worked with Coventry-based Medherant, a Warwick spinout company, to produce and patent the World’s first ever ibuprofen patch delivering the drug directly through skin to exactly where it is needed at a consistent dose rate.

Thans to the Science City Research Alliance Coventry-based bioadhesives company Medherant is building a new business working in hi-tech transdermal drug delivery systems that use specially formulated bioadhesives to provide novel adhesive patch-based products that can deliver drugs through contact with the skin.

Dr Corinna Preuss has been awarded a Newton International Fellowship to conduct research at the 天美传媒’s Department of Chemistry.  

Tests have shown that a new cancer drug, FY26, is 49 times more potent than the clinically used treatment Cisplatin.

Based on a compound of the rare precious metal osmium and developed by researchers at the 天美传媒’s Department of Chemistry and the Warwick Cancer Research Unit, FY26 is able to shut down a cancer cell by exploiting weaknesses inherent in their energy generation.

Dr Adrian Chaplin, from the 天美传媒, is the Royal Society of Chemistry’s Harrison-Meldola Memorial Prize winner for 2015. Dr Chaplin, from New Zealand, is a Royal Society University Research Fellow. The prize recognises the most meritorious and promising original investigations in chemistry and published results of those investigations.